Google
PPBT — PURPLE BIOTECH (Healthcare >> Biotechnology)
PPBT FAQ
What is PPBT's ROE?
PURPLE BIOTECH reports a Return on Equity (ROE) of -269.44%.
What is PPBT's dividend yield?
PURPLE BIOTECH offers a dividend yield of 0.00%.
What is PPBT's Deepscope Quality Score?
Deepscope rates PPBT's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy PPBT?
Deepscope's AI Timing Score for PPBT is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does PPBT belong to?
PURPLE BIOTECH is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 2.95
Price
-0.06
(-1.99%)
Day Change
|
|
|---|
PPBT, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not quite good , ...
| Quality Factors |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 96 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 2.95 |
| PBV / Sector |
0.29 / 4.48
GREAT
|
| Earning Per Share | -27.54 |
| PE / Sector |
N/A / 16.68
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
1.00 M
GREAT
|
| Average 1W Daily Value |
0.04 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
50% |
| Ability to Make Profit |
|
52% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-04 09:24:21 |
| Symbol | PPBT |
| Name | PURPLE BIOTECH |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 0.93 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 2.81 / 8,483.11 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 4 Oppenheimer Street, Rehovot, Israel, 7670104
Phone: 972 3 933 3121
Website: https://purple-biotech.com
Sector: Healthcare >> Biotechnology
Description: Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and CAPTN-3 - IM1240 and IM1305, multi-valent antibody designed to activate anti-tumoral immune response against TAA positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company was incorporated in 1968 and is headquartered in Rehovot, Israel.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
